![]() |
|
|
Vol. 14, Issue 11, 4569-4580, November 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institute of Biochemistry, Christian-Albrechts-University of Kiel, D-24118 Kiel, Germany
Submitted January 15, 2003;
Revised June 7, 2003;
Accepted July 2, 2003
Monitoring Editor: Peter Devreotes
Unlike most other matrix metalloproteinases (MMPs) MMP-19 is expressed in undifferentiated basal keratinocytes of healthy human skin. The human keratinocyte cell line HaCaT, which like basal keratinocytes constitutively expresses MMP-19, down-regulated the expression of MMP-19 at high calcium concentrations. Calcium-regulation occurred through E-cadherin mediated cell-cell contacts because neutralizing anti-E-cadherin antibodies restored MMP-19 expression in high calcium. Overexpression of MMP-19 in HaCaT cells (HaCaT-WT) increased cellular proliferation, as well as migration and adhesion on type I collagen. This was due to proteolysis of the insulin-like growth factor (IGF) binding protein-3 by MMP-19, which augmented signaling through the IGF-I receptor, as evidenced by its increased autophosphorylation. Conversely, these effects were not observed in cells transfected with MMP-2 or a catalytically inactive MMP-19 mutant. As further proof that increased IGF-signaling promoted adhesion and migration in HaCaT-WT cells, we reproduced these effects by treating parental HaCaT with IGF-I. We observed dephosphorylation of the focal adhesion kinase in HaCaT-WT as well as IGF-Itreated HaCaT cells, suggesting that inactivating focal adhesion kinase is a mechanism by which IGF-I enhances adhesion. Furthermore, IGF-I-triggered motility on type I collagen was mediated by MMP activity, which, however, was distinct from MMP-19. Considering the coexpression of IGFBP-3 and MMP-19 in the skin, we conclude that MMP-19 is a likely candidate to be the major IGFBP-3 degrading MMP in the quiescent epidermis. This activity might have widespread consequences for the behavior of epidermal keratinocytes.
This article has been cited by other articles:
![]() |
S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease Endocr. Rev., August 1, 2009; 30(5): 417 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Bernal, B Elias, H. Hartung, and B. Kieseier Regulation of matrix metalloproteinases and their inhibitors by interferon-{beta}: a longitudinal study in multiple sclerosis patients Multiple Sclerosis, June 1, 2009; 15(6): 721 - 727. [Abstract] [PDF] |
||||
![]() |
G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Piccard, P. E. Van den Steen, and G. Opdenakker Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins J. Leukoc. Biol., April 1, 2007; 81(4): 870 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mitsui, S. Mochizuki, T. Kodama, M. Shimoda, T. Ohtsuka, T. Shiomi, M. Chijiiwa, T. Ikeda, M. Kitajima, and Y. Okada ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3. Cancer Res., October 15, 2006; 66(20): 9913 - 9920. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jost, A. R. Folgueras, F. Frerart, A. M. Pendas, S. Blacher, X. Houard, S. Berndt, C. Munaut, D. Cataldo, J. Alvarez, et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res., May 15, 2006; 66(10): 5234 - 5241. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Larsen, A. G. DaSilva, K. Conant, and V. W. Yong Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci., February 22, 2006; 26(8): 2207 - 2214. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nagase, R. Visse, and G. Murphy Structure and function of matrix metalloproteinases and TIMPs Cardiovasc Res, February 15, 2006; 69(3): 562 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein, S. Bauersachs, S. E. Ulbrich, R. Einspanier, H. H.D. Meyer, S. E.M. Schmidt, H.-D. Reichenbach, M. Vermehren, F. Sinowatz, H. Blum, et al. Monozygotic Twin Model Reveals Novel Embryo-Induced Transcriptome Changes of Bovine Endometrium in the Preattachment Period Biol Reprod, February 1, 2006; 74(2): 253 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chaussain-Miller, F. Fioretti, M. Goldberg, and S. Menashi The Role of Matrix Metalloproteinases (MMPs) in Human Caries Journal of Dental Research, January 1, 2006; 85(1): 22 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ii, H. Yamamoto, Y. Adachi, Y. Maruyama, and Y. Shinomura Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis Exp Biol Med, January 1, 2006; 231(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
P J Jenkins, S Khalaf, W Ogunkolade, K McCarthy, T David, R E Hands, D Davies, and S A Bustin Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis Endocr. Relat. Cancer, December 1, 2005; 12(4): 891 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Masaki, T. Kurisaki, K. Shirakawa, and A. Sehara-Fujisawa Role of Meltrin {alpha} (ADAM12) in Obesity Induced by High- Fat Diet Endocrinology, April 1, 2005; 146(4): 1752 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Pendas, A. R. Folgueras, E. Llano, J. Caterina, F. Frerard, F. Rodriguez, A. Astudillo, A. Noel, H. Birkedal-Hansen, and C. Lopez-Otin Diet-Induced Obesity and Reduced Skin Cancer Susceptibility in Matrix Metalloproteinase 19-Deficient Mice Mol. Cell. Biol., June 15, 2004; 24(12): 5304 - 5313. [Abstract] [Full Text] [PDF] |
||||